Lara Krupka-Longpre
Corporate Officer/Principal presso MIRUM PHARMACEUTICALS, INC.
Patrimonio netto: 3 M $ in data 31/03/2024
Profilo
Lara Krupka-Longpre is currently the Chief Development Officer at Mirum Pharmaceuticals, Inc. She previously worked as the Chief Operating Officer at MedGenesis Therapeutix, Inc. and SillaJen Biotherapeutics, Inc. Additionally, she held the position of Vice President-Proposals & Contracts at PRA Health Sciences, Inc. Krupka-Longpre holds an MBA from Queen's University, an undergraduate degree from Cornell University, and a graduate degree from Harvard Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 02/02/2024 | 104 407 ( 0.22% ) | 3 M $ | 31/03/2024 |
Posizioni attive di Lara Krupka-Longpre
| Società | Posizione | Inizio |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2018 |
Precedenti posizioni note di Lara Krupka-Longpre
| Società | Posizione | Fine |
|---|---|---|
MedGenesis Therapeutix, Inc.
 MedGenesis Therapeutix, Inc. Medical SpecialtiesHealth Technology MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation. | Chief Operating Officer | 01/06/2018 |
| PRA HEALTH SCIENCES, INC. | Corporate Officer/Principal | - |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Chief Operating Officer | - |
Formazione di Lara Krupka-Longpre
| Queen's University | Masters Business Admin |
| Cornell University | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MIRUM PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
PRA Health Sciences, Inc.
 PRA Health Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services. The Data Solutions segment involves in data and analytics; technology solutions and real-world insights, and services primarily to the company's life science clients. The company was founded in 1976 and is headquartered in Raleigh, NC. | Commercial Services |
MedGenesis Therapeutix, Inc.
MedGenesis Therapeutix, Inc. Medical SpecialtiesHealth Technology MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation. | Health Technology |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
- Borsa valori
- Insiders
- Lara Krupka-Longpre
